Total Payments
$23,826
2024 Payments
$258.31
Companies
16
Transactions
33
Medicare Patients
662
Medicare Billing
$227,708
Payment Breakdown by Category
Consulting$21,388 (89.8%)
Food & Beverage$1,412 (5.9%)
Research$852.94 (3.6%)
Travel$174.14 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,388 | 4 | 89.8% |
| Food and Beverage | $1,412 | 27 | 5.9% |
| Unspecified | $852.94 | 1 | 3.6% |
| Travel and Lodging | $174.14 | 1 | 0.7% |
Payments by Type
General
$22,974
32 transactions
Research
$852.94
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $16,250 | 3 | $0 (2021) |
| ModernaTX, Inc. | $5,323 | 3 | $0 (2023) |
| F. Hoffmann-La Roche AG | $852.94 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $305.16 | 3 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $159.86 | 3 | $0 (2021) |
| La Jolla Pharmaceutical Company | $157.28 | 3 | $0 (2024) |
| Edwards Lifesciences Corporation | $148.91 | 1 | $0 (2021) |
| Actelion Pharmaceuticals US, Inc. | $144.78 | 1 | $0 (2024) |
| ABBVIE INC. | $138.69 | 7 | $0 (2024) |
| Dova Pharmaceuticals | $112.33 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $258.31 | 5 | Actelion Pharmaceuticals US, Inc. ($144.78) |
| 2023 | $5,397 | 6 | ModernaTX, Inc. ($5,323) |
| 2022 | $352.56 | 9 | AstraZeneca Pharmaceuticals LP ($182.30) |
| 2021 | $17,528 | 9 | GlaxoSmithKline, LLC. ($16,250) |
| 2019 | $230.37 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($118.86) |
| 2018 | $59.94 | 1 | Fisher & Paykel Healthcare Inc ($59.94) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $45.77 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 06/03/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/28/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Pulmonology | ||||||
| 01/29/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $144.78 | General |
| Category: Cardiology | ||||||
| 01/29/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/19/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $5,137.50 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/19/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Travel and Lodging | Cash or cash equivalent | $174.14 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/19/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Food and Beverage | Cash or cash equivalent | $11.70 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/13/2023 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: Endo-Mechanical | ||||||
| 08/22/2023 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: BIOLOGIC | ||||||
| 03/28/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/19/2022 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/24/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/29/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/23/2022 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $47.30 | General |
| Category: Respiratory | ||||||
| 07/01/2022 | Abbott Laboratories | 2ND GEN CENTRIMAG PRIMARY CONSOLE (Device) | Food and Beverage | In-kind items and services | $49.84 | General |
| Category: Heart Failure | ||||||
| 06/13/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/25/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/23/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/29/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 12/07/2021 | Edwards Lifesciences Corporation | HemoSphere (Device) | Food and Beverage | In-kind items and services | $148.91 | General |
| Category: Hemodynamic Monitoring | ||||||
| 12/06/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: RESPIRATORY | ||||||
| 11/30/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/17/2021 | Dova Pharmaceuticals | Doptelet (Drug) | Food and Beverage | In-kind items and services | $112.33 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SAFETY AND EFFICACY OF TOCILIZUMAB 4 MGKG OR 8 MGKG IN HOSPITALIZED PATIENTS WITH MODERATE-TO-SEVERE COVID-19 PNEUMONIA A RANDOMIZED CLINICAL TRIAL | F. Hoffmann-La Roche AG | $852.94 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 181 | 390 | $220,527 | $54,752 |
| 2022 | 5 | 176 | 423 | $236,176 | $60,864 |
| 2021 | 6 | 160 | 389 | $224,598 | $57,967 |
| 2020 | 3 | 145 | 348 | $199,366 | $54,125 |
Total Patients
662
Total Services
1,550
Medicare Billing
$227,708
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 94 | 283 | $190,218 | $48,088 | 25.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 56 | $11,816 | $3,451 | 29.2% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 12 | 14 | $10,388 | $1,390 | 13.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 20 | 25 | $2,875 | $1,006 | 35.0% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 12 | 12 | $5,230 | $816.84 | 15.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 93 | 304 | $204,025 | $53,591 | 26.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 43 | 73 | $15,403 | $4,202 | 27.3% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 18 | 22 | $9,944 | $1,513 | 15.2% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 11 | 13 | $4,264 | $1,160 | 27.2% |
| 36620 | Insertion of artery tube for blood sampling or infusion through skin | Facility | 2022 | 11 | 11 | $2,540 | $397.95 | 15.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 81 | 287 | $187,698 | $50,996 | 27.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 48 | $10,128 | $2,843 | 28.1% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 12 | 14 | $4,592 | $1,271 | 27.7% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2021 | 12 | 12 | $8,904 | $1,261 | 14.2% |
| 36556 | Insertion of central venous catheter for infusion, patient 5 years or older, not tunneled | Facility | 2021 | 15 | 17 | $10,438 | $1,191 | 11.4% |
| 36620 | Insertion of arterial catheter for blood sampling or infusion, accessed through the skin | Facility | 2021 | 11 | 11 | $2,838 | $405.02 | 14.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 89 | 267 | $174,618 | $49,085 | 28.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 37 | 62 | $13,082 | $3,682 | 28.1% |
| 36556 | Insertion of central venous catheter for infusion, patient 5 years or older | Facility | 2020 | 19 | 19 | $11,666 | $1,358 | 11.6% |
About Dr. Deepa Gotur, MD
Dr. Deepa Gotur, MD is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1063671600.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deepa Gotur, MD has received a total of $23,826 in payments from pharmaceutical and medical device companies, with $258.31 received in 2024. These payments were reported across 33 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($21,388).
As a Medicare-enrolled provider, Gotur has provided services to 662 Medicare beneficiaries, totaling 1,550 services with total Medicare billing of $227,708. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine
- Location Houston, TX
- Active Since 06/09/2008
- Last Updated 09/01/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1063671600
Products in Payments
- Moderna Covid-19 Vaccine (Biological) $5,323
- Actemra (Biological) $852.94
- GIAPREZA (Drug) $157.28
- HemoSphere (Device) $148.91
- OPSUMIT (Drug) $144.78
- LOKELMA (Drug) $122.86
- Doptelet (Drug) $112.33
- AVYCAZ (Drug) $99.31
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment (Device) $59.94
- Fetroja (Drug) $50.27
- 2ND GEN CENTRIMAG PRIMARY CONSOLE (Device) $49.84
- TEZSPIRE (Biological) $47.30
- OFEV (Drug) $41.00
- TEFLARO (Drug) $39.38
- Monarch Platform (Device) $33.76
- Prolastin-C Liquid (Biological) $20.71
- RUCONEST (Biological) $18.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Aung Naing, Md, MD
Internal Medicine — Payments: $925,146
Internal Medicine $925,146
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947